Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML - Trial NCT05473221
Access comprehensive clinical trial information for NCT05473221 through Pure Global AI's free database. This Phase 1 trial is sponsored by Zhejiang University and is currently Not yet recruiting. The study focuses on AML. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang University
Timeline & Enrollment
Phase 1
Aug 02, 2022
Aug 02, 2025
Primary Outcome
Evaluation of Safety,Changes in cytokine level after CD33 CAR-T infusion
Summary
This is an open label, phase I study to assess the safety and efficacy of CD33 CAR-T in
 patients with relapsed and refractory acute myeloid leukemia
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05473221
Non-Device Trial